Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Harper Hubbeling"'
Autor:
Harper Hubbeling, Noura Choudhury, Jessica Flynn, Zhigang Zhang, Christina Falcon, Valerie W. Rusch, Bernard J. Park, Etay Ziv, Narek Shaverdian, Daphna Y. Gelblum, Annemarie F. Shepherd, Charles B. Simone, Abraham J. Wu, Daniel R. Gomez, Alexander Drilon, Andreas Rimner
Publikováno v:
JCO Precision Oncology.
PURPOSE Local therapy prolongs progression-free survival in patients with oligometastatic non–small-cell lung cancers treated with chemotherapy. We previously reported that local therapy also prolongs survival and time to next therapy in patients o
Autor:
James S. Hardwick, Alice T. Shaw, Anna F. Farago, Aaron N. Hata, Lorin A. Ferris, Diane Tseng, Katherine Schultz, Beow Y. Yeap, Luc Friboulet, Justin F. Gainor, Satoshi Yoda, Donghui Huang, Leila Dardaei, Zofia Piotrowska, Ibiayi Dagogo-Jack, A. John Iafrate, Jessica J. Lin, Harper Hubbeling, Mari Mino-Kenudson
Publikováno v:
JCO Precision Oncology. :1-13
Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transiti
Autor:
Jochen K. Lennerz, Jessica J. Lin, Theodore O. Johnson, Charlotte E. Lee, Justin F. Gainor, Beow Y. Yeap, Harper Hubbeling, Ibiayi Dagogo-Jack, Alice T. Shaw
Publikováno v:
Journal of Clinical Oncology. 38:9611-9611
9611 Background: Lorlatinib is a potent, brain-penetrant ROS1/ALK tyrosine kinase inhibitor (TKI), which has demonstrated efficacy in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC), including in patients (pts) previously tre